Cochrane Review Group
Infectious Diseases
135 systematic reviews in Infectious Diseases ask 1,518 questions. 8.9% have no studies to answer them, 23.1% rest on very low certainty evidence and 30.5% reach moderate or high certainty.
Reviews
135
Questions
1,518
current versions
No studies
8.9%
Moderate or high
30.5%
No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 0.84 [0.49, 1.46] | 11 studies · 3459 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 0.86 [0.68, 1.09] | 8 studies · 1383 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | HR 1.13 [0.69, 1.83] | 4 studies · 721 participants | Very low |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR NRCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 135
Interventions to improve disposal of child faeces for preventing diarrhoea and soil‐transmitted helminth infection
CochraneSoF table
13 questions
Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV
CochraneSoF table
10 questions
Larviciding to prevent malaria transmission
CochraneSoF table
4 questions
Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV‐positive individuals
CochraneSoF table
5 questions
Linezolid for drug‐resistant pulmonary tuberculosis
CochraneSoF table
10 questions
MVA85A vaccine to enhance BCG for preventing tuberculosis
CochraneSoF table
7 questions
Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
CochraneSoF table
10 questions
Rapid initiation of antiretroviral therapy for people living with HIV
CochraneSoF table
6 questions
Insecticide‐treated nets for preventing malaria
CochraneSoF table
16 questions
Vaccines for preventing typhoid fever
CochraneSoF table
21 questions
Antibiotics for treating scrub typhus
CochraneSoF table
15 questions
Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people
CochraneSoF table
8 questions
Treatment for HIV‐associated cryptococcal meningitis
CochraneSoF table
21 questions
Antiretroviral resistance testing in HIV‐positive people
CochraneSoF table
8 questions
Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission
CochraneSoF table
21 questions
Early versus delayed antiretroviral treatment in HIV‐positive people with cryptococcal meningitis
CochraneSoF table
4 questions
Mefloquine for preventing malaria in pregnant women
CochraneSoF table
16 questions
Smectite for acute infectious diarrhoea in children
CochraneSoF table
9 questions
Mosquito repellents for malaria prevention
CochraneSoF table
7 questions
Fly control to prevent diarrhoea in children
CochraneSoF table
1 questions
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)
CochraneSoF table
2 questions
Nutritional supplements for patients being treated for active visceral leishmaniasis
CochraneSoF table
6 questions
Insecticide space spraying for preventing malaria transmission
CochraneSoF table
1 questions
Ribavirin for treating Crimean Congo haemorrhagic fever
CochraneSoF table
4 questions
Ivermectin and permethrin for treating scabies
CochraneSoF table
23 questions